EZH2 and epithelioid sarcoma: EZH2 encodes a core component of PRC2, but might exert PRC2-independent oncogenic activity,80 and the EZH2 inhibitor tazemetostat has been approved by the US Food and Drug Administration for treatment of advanced epithelioid sarcomas with EZH2 mutation.